Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.
Publication
, Journal Article
Greenough, TC; Cunningham, CK; Muresan, P; McManus, M; Persaud, D; Fenton, T; Barker, P; Gaur, A; Panicali, D; Sullivan, JL; Luzuriaga, K ...
Published in: Vaccine
December 9, 2008
A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Vaccine
DOI
ISSN
0264-410X
Publication Date
December 9, 2008
Volume
26
Issue
52
Start / End Page
6883 / 6893
Location
Netherlands
Related Subject Headings
- Young Adult
- Virology
- Vaccinia
- Vaccines, Synthetic
- T-Lymphocytes
- RNA, Viral
- Prospective Studies
- Male
- Interferon-gamma
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Greenough, T. C., Cunningham, C. K., Muresan, P., McManus, M., Persaud, D., Fenton, T., … Pediatric AIDS Clinical Trials Group P1059 Team, . (2008). Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine, 26(52), 6883–6893. https://doi.org/10.1016/j.vaccine.2008.09.084
Greenough, Thomas C., Coleen K. Cunningham, Petronella Muresan, Margaret McManus, Deborah Persaud, Terry Fenton, Piers Barker, et al. “Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.” Vaccine 26, no. 52 (December 9, 2008): 6883–93. https://doi.org/10.1016/j.vaccine.2008.09.084.
Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008 Dec 9;26(52):6883–93.
Greenough, Thomas C., et al. “Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.” Vaccine, vol. 26, no. 52, Dec. 2008, pp. 6883–93. Pubmed, doi:10.1016/j.vaccine.2008.09.084.
Greenough TC, Cunningham CK, Muresan P, McManus M, Persaud D, Fenton T, Barker P, Gaur A, Panicali D, Sullivan JL, Luzuriaga K, Pediatric AIDS Clinical Trials Group P1059 Team. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine. 2008 Dec 9;26(52):6883–6893.
Published In
Vaccine
DOI
ISSN
0264-410X
Publication Date
December 9, 2008
Volume
26
Issue
52
Start / End Page
6883 / 6893
Location
Netherlands
Related Subject Headings
- Young Adult
- Virology
- Vaccinia
- Vaccines, Synthetic
- T-Lymphocytes
- RNA, Viral
- Prospective Studies
- Male
- Interferon-gamma
- Humans